Skip to main content

Streptococcal Infections

4
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
4100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
1
PneumococcalPhase 2
Low dose Strep A AlumPhase 1
Sandoz
SandozAustria - Kundl
2 programs
1
1
Group B streptococcus vaccinePhase 2Vaccine1 trial
Group B Streptococcus Trivalent Vaccine - 20/20/20 μgPhase 1/2Vaccine1 trial
Active Trials
NCT01193920Completed380Est. Dec 2012
NCT01412801Completed270Est. Dec 2012
Novartis
NovartisBASEL, Switzerland
2 programs
Group B Streptococcus Trivalent Vaccine - 20/20/20 μgPHASE_1_2Vaccine
Group B streptococcus vaccinePHASE_2Vaccine
GSK
GSKLONDON, United Kingdom
1 program
PneumococcalPHASE_21 trial
Active Trials
NCT00169481Completed689Est. May 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozGroup B streptococcus vaccine
GSKPneumococcal
SandozGroup B Streptococcus Trivalent Vaccine - 20/20/20 μg

Clinical Trials (3)

Total enrollment: 1,339 patients across 3 trials

NCT01412801SandozGroup B streptococcus vaccine

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings

Start: Sep 2011Est. completion: Dec 2012270 patients
Phase 2Completed
NCT00169481GSKPneumococcal

A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine

Start: Oct 2004Est. completion: May 2005689 patients
Phase 2Completed
NCT01193920SandozGroup B Streptococcus Trivalent Vaccine - 20/20/20 μg

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age

Start: Oct 2010Est. completion: Dec 2012380 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Vaccine is the dominant modality (100% of programs)
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.